ROIV Stock Forecast & Price Target

Roivant Sciences is supported by a pipeline that is beginning to convert into commercially meaningful assets, led by Lisraya as the first targeted therapy approved for adult dermatomyositis and already commercially available through a specialty pharmacy network. The PHocus Phase II mosliciguat data also strengthen the thesis, with a 56.3% placebo-adjusted reduction in PVR, +35.2 meters in 6MWD at Week 16, and supportive NT-proBNP improvement, while Phase III PHrontier is underway with about 375 patients. Together with broad subgroup consistency, favorable tolerability, and roughly $3B peak sales potential in PH-ILD, these results suggest a company with multiple shots on goal and improving de-risked economics.

Roivant Sciences is facing a negative fundamental outlook because several pipeline programs have suffered clinical failures, including IMVT assets in non-infectious uveitis and cutaneous sarcoidosis, mosliciguat in PH-ILD, and unanticipated safety issues across batoclimab, IMVT-1402, brepocitinib, and other assets. Litigation setbacks and unaudited financial statements further weaken confidence in execution and disclosure quality, while the company still depends on products that are not yet approved and must compete against larger, more experienced commercial organizations. Although management cites a 2036 discounted risk-adjusted revenue estimate of $2.5B, the path to that outcome remains highly uncertain given regulatory, clinical, technical, and commercial risks.